A shift last year by the federal government in how it pays for drugs to treat dialysis patients may have had an unintended and potentially dire consequence, according to new research: a significant jump in blood transfusions for patients who now may not be getting enough of the medications.
The findings are seen by some experts as a stark illustration of how the government’s reimbursement policies can drive the practice of medicine.
Continue reading at The New York Times…
Galen’s Grace-Marie Turner warned of the dangers of government involvement in medical decisions in a commentary for Forbes.com last September. Read more…